Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Asset Writedowns and Impairment (2018 - 2025)

Bio-Techne (TECH) has 5 years of Asset Writedowns and Impairment data on record, last reported at $84.2 million in Q2 2025.

  • For Q2 2025, Asset Writedowns and Impairment rose 428.46% year-over-year to $84.2 million; the TTM value through Jun 2025 reached $96.4 million, up 505.51%, while the annual FY2025 figure was $80.5 million, 266.54% up from the prior year.
  • Asset Writedowns and Impairment reached $84.2 million in Q2 2025 per TECH's latest filing, up from -$3.7 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $84.2 million in Q2 2025 and bottomed at -$3.7 million in Q1 2025.
  • Average Asset Writedowns and Impairment over 3 years is $23.1 million, with a median of $15.9 million recorded in 2024.
  • The widest YoY moves for Asset Writedowns and Impairment: up 428.46% in 2025, down 428.46% in 2025.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $18.7 million in 2021, then decreased by 14.91% to $15.9 million in 2024, then soared by 428.46% to $84.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $84.2 million in Q2 2025, -$3.7 million in Q1 2025, and $15.9 million in Q2 2024.